Now fully revised and in its fourth edition, the Oxford Handbook of Oncology has been the essential go-to guide for students and practitioners in oncology for over a decade. The scientific basis and diagnosis of cancers is covered, as well as drugs, biomarkers, and the presentation and psychosocial aspects of oncology. Concise, practical, and comprehensive, there is no better companion for both common conditions and challenging emergencies.
The field of oncology has surged forward since the last edition was published and the Oxford Handbook of Oncology has been fully revised and updated to reflect these recent advances so you can be sure that the vital information you need is in your hands. This handbook incorporates changes such as the understanding of the science of cancer, novel therapies in breast, lung, renal, and melanoma, molecular sub-classification of common solid cancers, personalized therapy approaches, new agents in hard to treat cancers, the benefits of new technologies in radiotherapy, and the emerging data on the importance of the immune response.
Written by experts in the field to ensure that it is grounded in real life clinical practice, this handbook provides a concise guide to all aspects of oncology for all students, nurses, and junior faculty responsible for the care of cancer patients, while also providing further reading and highlighting areas of controversy for those who need a more detailed understanding.
1: Multidisciplinary approach to cancer
2: Aetiology and epidemiology
3: Genetics of cancer
4: Surgical oncology
5: Principles of radiation oncology
6: Principles of chemotherapy
7: Principles of symptom control in palliative care
8: Late effects of radiotherapy and chemotherapy
9: Hormone therapy
10: Biological and targeted therapies
11: Clinical trials
12: Cancer prevention
13: Population screening for cancer
14: Thoracic cancer
15: Breast cancer
16: Colorectal cancer
17: Anal cancer
18: Upper gastrointestinal cancer
19: Endocrine cancers
20: Genitourinary cancers
21: Gynaecological cancer
22: Head and neck cancer
23: Tumours of the central nervous system
24: Skin cancer
25: Haematological malignancies
26: Bone and soft tissue malignancies
27: Cancer of unknown primary site
28: Paraneoplastic syndromes
29: AIDS-related malignancies
30: Childhood cancers presenting in adulthood
31: Overview of Acute Oncology
32: Spinal cord compression and bone marrow suppression
33: Superior vena cava obstruction and raised intracranial pressure
34: Stridor
35: Thromboembolic and cardiac emergencies
36: Obstruction
37: Biochemical crises
38: Complications of long-term central venous lines and chemotherapy extravasation
39: Novel therapeutic strategies
40: Gene therapy and immunotherapy for cancer
41: Biomarkers and Cancer
Appendices
Edited by Jim Cassidy, Emeritus Professor, University of Glasgow, Donald Bissett, Consultant in Clinical Oncology,, Aberdeen Royal Infirmary, Aberdeen, UK, Roy A. J. Spence OBE, Consultant Surgeon; Honorary Professor, Belfast Trust; Queen University, Belfast, University of Ulster, Northern Ireland, UK, Miranda Payne, Locum Consultant in Medical Oncology, Oxford University Hospitals NHS Trust, UK, and Gareth Morris-Stiff, Attending Surgeon; Associate Professor, Cleveland Clinic, Cleveland, Ohio; Lerner College of Medicine, Case Western Reserve University, USA
Jim Cassidy was previously Professor of Oncology at Aberdeen university (1994-2002), then CRUK Head of Oncology, Beatson Laboratories, Glasgow. He moved into pharma over 2 years ago to head early drug development.
Donald Bissett was schooled in Glasgow, and graduated from St Andrews University 1979 and University of Manchester 1982. Clinical experience in South Manchester Hospitals led to MRCP 1986, then commenced clinical oncology training in Nottingham and Glasgow, with FRCR 1989. Research Fellowship in the Department of Medical Oncology Beatson Institute, with MD and MSc in Clinical Pharmacology 1992. Senior lecturer in Clinical Oncology 1994, then Consultant in Clinical Oncology in Aberdeen 1995-2013 with particular interests in urological and thoracic malignancies.
Contributors:
Dr Dominic Culligan
Consultant in Haemato-oncology, Aberdeen Royal Infirmary, UK
Professor Owen
Sansom Beatson Institute, Glasgow, UK
Professor Jeff Evans
Professor of Translational Cancer Research, University of Glasgow, UK
Dr Tim Morgan
Consultant in Palliative Care, Roxburghe House, Aberdeen, UK
Dr Nadeem Siddiqui
Consultant Gynaecological Oncologist, Glasgow Royal Infirmary, UK